ARTICLE
|
doi:10.20944/preprints201808.0307.v3
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
Immune Checkpoint Inhibitors; anti-PD-1/PDL-1; anti-CTLA-4; gender; sex; Nivolumab; Pembrolizumab; Atezolizumab; Ipilimumab; Durvalumab
Online: 15 November 2018 (07:02:24 CET)